Skip to main content
Signal8

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

$INCYPress releaseJun 19, 2026, 2:00 AM ETRead the release

Japan’s Ministry of Health, Labour and Welfare approved Minjuvi (tafasitamab) in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The approval is based on data from the L-MIND Phase II trial, which showed a 58.8% overall response rate, and the J-MIND Phase Ib/II trial in Japan, which showed a 71.4% response rate.

Key figures

Drug Name
Minjuvi (tafasitamab)
Phase Of Trial
Phase II
J mind cr
45.2%
L mind cr
41.3%
J mind orr
71.4%
L mind orr
58.8%

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.